Terray Therapeutics, a Los Angeles, CA-based biotechnology company improving human health by enhancing small molecule drug development, raised $120M in Series B funding.
The round was led by Bedford Ridge Capital and existing investor NVentures (NVIDIA’s venture capital arm), with participation from new and existing investors including, Goldcrest Capital, Madrona Ventures, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, and Alexandria Ventures. Sid Shenai, who partnered with Bedford Ridge Capital on this financing, will join Terray’s Board of Directors.
The company intends to use the funds to progress internal programs into clinical trials and further enhance its integrated AI platform, tNova, which it uses to power both internal and partnered programs.
Led by CEO Jacob Berlin, Terray is a biotechnology company which change the way to discover and develop small molecule therapeutics. It explores molecules and targets with a sophisticated integration of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. Its platform blends experimentation and computation to deliver on the promise of generative AI for small molecule discovery, finding solutions to the toughest therapeutic challenges.
Terray applies this expertise to its own internal pipeline focused on immunological diseases and to additional challenging targets in partnership with Bristol Myers Squibb and Calico.
